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Combination of automated solid-phase and
enzymatic oligosaccharide synthesis provides
access to a(2,3)-sialylated glycans†
Richard J. Fair,a Heung Sik Hahmab and Peter H. Seeberger*ab
A synthetic strategy combining automated solid-phase chemical
synthesis and enzymatic sialylation was developed to access
a(2,3)-sialylated glycans.
N-Acetyl-neuraminic acid (Neu5Ac) is the most studied among
the over 50 sialic acids described to date and is a component of
many glycans of biological relevance. a(2,6)-Sialylated and a(2,3)-
silylated glycans are predominantly found in nature.1–3 Sialylated
glycans on the cell surface regulate various cellular functions4
and are linked to a host of extracellular recognition events.5,6 Sialic
acid containing glycans are associated with many cancers,7–9 auto-
immune disorders,10 and diabetes11 but are also exploited by
pathogenic organisms including trypanosomes,12 bacteria,13 and
viruses.14 Biological studies greatly benefit from the availability
of defined glycans as molecular probes.
Sialylated oligosaccharides have been a challenge for synthetic
chemists since no participating group can be placed at the
neighboring C-3 position and next to the sterically hindered,
quaternary anomeric center is an electron withdrawing carbonyl
that diminishes the reactivity. Significant progress has been made
in developing eﬃcient chemical sialylation reactions but glycosyl-
ation eﬃciencies for these linkages still remain significantly lower
than those obtained for other couplings.2,15,16 The automated
assembly of glycans on solid support benefits frommass action of
the glycosylating agent and has resulted in the rapid assembly of
ever more complex glycans.16,17 However, the automated assembly
of sialylated glycans has been challenging. Sialic acid-galactose
disaccharide building blocks were used to produce a(2,3)- and
a(2,6)-sialylated glycans by automated solid-phase synthesis.18
The use of disaccharide building blocks is not ideal within
the logic framework of glycan assembly based onmonosaccharide
building blocks. More recently, a sialic acid monosaccharide
building block proved useful in producing a(2,6)-sialylated
glycans.19 a(2,3)-Silylated glycans were formed in low yields
(o20%) using this method.
To address the challenge that could not be met with chemical
means alone, the combination of automated glycan assembly and
enzymatic glycan synthesis, two complementary techniques, might
oﬀer a solution. Here, we demonstrate that glycans assembled by
automated synthesis can be used as scaﬀolds for enzymatic elabora-
tion to access the desired sialylated glycans. Sialyltransferases transfer
sialic acids fromactivated cytodinemonophosphate (CMP)-sialic acids
to oligosaccharide substrates.1 Bacterial sialyltransferases have been
reliable tools to eﬃciently and selectively install desired sialic acids2,20
even on gram scale.21 By combining the power of automated glycan
assembly to prepare the glycan backbone with the eﬃciency and
selectivity of glycan sialylation, this strategy combines the advantages
inherent to both methods for the rapid production sialylated glycans.
Five oligosaccahrides GM3 (1), GM1b (cisGM1, 2), sialyl LC4 (3),
SPG (sialyl nLC4, 4), and SLPG (nHM1, 5) (Fig. 1) were selected to
explore the combination of automated glycan assembly and enzy-
matic sialylation. These sialosides are structurally similar as they
have linear, non-fucosylated backbones and terminal sialic acids
since the sialyltransferase used for these proof-of-principle studies, a
truncated Pasturella multocida sialyltransferase 1 (PmST1), operates
on such linear structures.
a(2,3)-Sialyltransferases glycosylate terminal galactose residues
and moieties immediately next to the galactose eﬀect the sialylation
eﬃciency.22 To evaluate the influence of the nearest neighbor of
galactose on the enzymatic reactions, diﬀerent sugars and linkages
next to the galactose residue were explored. The target molecules are
either tumor-associated carbohydrate antigens (TACAs) (1, 2, 4),7,23–25
associated with autoimmune disorders (1, 2, 4, 5),10,26–28 or exploited
by pathogens (1, 4).13,29,30
The synthetic strategy, exemplified for the synthesis of GM1b (2)
(Scheme 1) relies on the automated solid phase assembly of the
glycan backbone (11) using thioglycoside building blocks (6–9)
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and resin appended with a photo-cleavable linker (10)31 through
successive cycles of glycosylation. All reaction steps including
removal of the fluorenylmethloxycarbonyl (Fmoc) temporary pro-
tecting group and acidic washes are carried out on an automated
synthesizer.32 Building blocks were activated using N-iodo-
succinimide (NIS) and triflic acid (TfOH) and two couplings using
each 4.4 equivalents of building block in all cases except for SLPG
(5) where five equivalents of building block per cycle were used.
Building blocks (6, 8, 9, S3–S5, ESI†) have been developed pre-
viously33–35 and were known to couple efficiently and selectively.
Fmoc protecting groups were removed by exposure to a solution of
triethylamine (TEA) (20% in dimethylformamide (DMF)). An acid
wash with trimethylsilyltriflate (TMSOTf) follows to ensure the
removal of base prior to the introduction of the next building
block. UV irradiation of the resin in a continuous flow device
afforded fully protected oligosaccharides.31 Yields for protected
glycosides were high with only very small quantities of deletion
sequences observed by analytical HPLC. Overall yields following
HPLC purification ranged from 36% to 46% with the number of
automated steps ranging from four steps for the disaccharide
precursor to GM3 to twelve steps for the hexasaccharide precursor
of SLPG (Table 1).
All remaining protective groups were removed to obtain
completely deprotected oligosaccharides. Benzoyl esters were
Fig. 1 a(2,3)-Sialic acid containing target glycans.
Scheme 1 Automated glycan assembly synthetic strategy illustrated for GM1b (2). (A) Thioglycoside building blocks and photo-cleavable resin; (B) fully
protected, resin-bound glycoside; (C) a(2,3)-sialylated glycoside; (D) automated steps: (1) glycosylation (NIS, TfOH, DCM, Dioxane), (2) Fmoc
deprotection (TEA, DMF), (3) acidic wash (TMSOTf, DCM); (E) post-automation steps: (1) photo-cleavage (hn, DCM), (2) methanolysis (NaOMe, MeOH,






















































































This journal is©The Royal Society of Chemistry 2015 Chem. Commun., 2015, 51, 6183--6185 | 6185
removed by methanolysis using a solution of sodium methoxide
(NaOMe) in methanol and dichloromethane (DCM) at 40 1C.
Subsequent hydrogenolysis of benzyl ethers and the carboxy-
benzyl (Cbz) carbamate with concurrent reduction of trichloro-
acetyl (TCA) groups was achieved upon exposure to 45 psi
hydrogen with a Pd/C catalyst in a methanol, water, and acetic
acid solution. Following global deprotection, the products were
HPLC purified to yield substrates for the a(2,3)-sialyltransferase.
The deprotection steps yielded 78–91% of the desired glycans
over two steps (Table 1). The free glycans are appended with an
amine functionalized linker that serves as a convenient handle
for ligation to microarrays or carrier proteins used in vaccine
conjugates.
With several oligosaccharides in hand, a truncated a(2,3)-
sialyltransferase from Pasturella multocida (PmST1) was employed
for enzymatic sialylation. This commercially available enzyme has
a broad substrate specificity and has been used successfully in
enzymatic syntheses.22
The sialylation reactions employed a(2,3)-sialyltransferase,
CMP-Neu5Ac, and an alkaline phosphatase that serves to
dephosphorylate the CMP byproduct of the reaction. Reactions
proceeded in a Tris-HCl buﬀer at pH 8.0 at 37 1C with high
conversion (495% as determined by analytical HPLC) for all
substrates with 1,4-linked terminal galactose residues (GM3, SPG,
and SLPG precursors) using 1.1 equivalents of CMP-Neu5Ac and
30 mU sialyltransferase per mmol substrate. Sialylation was less
eﬃcient for substrates with 1,3-linked galactoses (GM1b and sLC4
precursors), however. To achieve high conversion (86%) in the case
of sLC4 more enzyme was necessary (120 mU sialyltransferase per
mmol substrate). In the case of GM1b, high conversion (87%),
required more enzyme and four equivalents of CMP-Neu5Ac.
Isolated yields, following HPLC purification of the target sialosides
ranged from 78–89% (Table 1).
Automated glycan assembly and enzymatic synthesis were
combined to produce five a(2,3)-sialylated glycans. Solid-phase
chemistry is used for the rapid and high yielding production of
the glycan backbones using just a few building blocks, while
the sialyltransferase is used for high yielding and highly regio-
and stereoselective sialylation. The combination of automated
and enzymatic glycosylations is expected to be of general utility.
Future work will seek to apply this approach to other enzymes.
We thank the Max-Planck Society and the European Research
Council (ERC Advanced Grant AUTOHEPARIN to PHS) for generous
financial support.
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GM3 (1) 42 82 87
GM1b (2) 46 91 78
sLC4 (3) 36 83 79
SPG (4) 44 86 87
SLPG (5) 37 78 89
a All yields given as % values. b Yield of protected glycan following
photo-cleavage from resin and HPLC purification as determined based
on resin loading. c Yield of deprotected glycan following methanolysis,
hydrogenolysis, and HPLC purification. d Yield of enzymatic sialyla-
tion following HPLC purificaiton.
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